MorphoSys AG Receives Consensus Rating of Hold from Analysts
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
Shares of MorphoSys AG have received an average recommendation of Hold from the nine analysts that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company.
Read at thelincolnianonline.com
 |
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
MorphoSys is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
| NVCT | Nuvectis Pharma | 3.98 | ||||
| KRON | Kronos Bio | 2.17 | ||||
| IPSC | Century Therapeutics | 0.99 | ||||
| CGEM | Cullinan Oncology | 0.83 | ||||
| LYRA | Lyra Therapeutics | 0.53 | ||||
| RLYB | Rallybio Corp | 0.43 | ||||
| MLYS | Mineralys Therapeutics, | 0.00 | ||||
| EWTX | Edgewise Therapeutics | 0.00 | ||||
| PMVP | Pmv Pharmaceuticals | 0.00 | ||||
| ACLX | Arcellx | 0.00 | ||||
| PCVX | Vaxcyte | 0.00 | ||||
| MRSN | Mersana Therapeutics | 0.00 | ||||
| GBIO | Generation Bio | 0.00 | ||||
| ELVN | Enliven Therapeutics | 0.94 | ||||
| IMCR | Immunocore Holdings | 1.23 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| GOSS | Gossamer Bio | 2.36 | ||||
| CCCC | C4 Therapeutics | 2.64 | ||||
| IMRX | Immuneering Corp | 3.86 | ||||
| REPL | Replimune | 4.14 | ||||
| VTYX | Ventyx Biosciences | 6.30 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |